Joseph Grossman

Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy

Joseph Grossman, Vice President of Early Clinical Development at Agenus,  shared a post on LinkedIn:

“The final version of our recent Cancer Discovery paper came out today “Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy”.
I couldn’t be prouder of our team at Agenus, or more excited for the future of oncology.”

Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy 

Authors: Dhan Chand, et al.

Joseph Grossman

AACR Agenus cancer cancer awareness cancer care Cancer Discovery Dhan Chand fight against cancer Global fight against cancer immunotherapy Joseph Grossman OncoDaily Oncology